Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 390

1.

Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use.

Jacobs EG, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, Rasgon NL.

PLoS One. 2013;8(2):e54713. doi: 10.1371/journal.pone.0054713. Epub 2013 Feb 13.

2.

APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging.

Bunce D, Fratiglioni L, Small BJ, Winblad B, Bäckman L.

Neurology. 2004 Sep 14;63(5):816-21.

PMID:
15365129
3.

Apolipoprotein E ε4 allele interacts with sex and cognitive status to influence all-cause and cause-specific mortality in U.S. older adults.

Beydoun MA, Beydoun HA, Kaufman JS, An Y, Resnick SM, O'Brien R, Ferrucci L, Zonderman AB.

J Am Geriatr Soc. 2013 Apr;61(4):525-34. doi: 10.1111/jgs.12156. Epub 2013 Mar 21.

4.

Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes.

Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM.

Neurology. 2011 Mar 22;76(12):1078-84. doi: 10.1212/WNL.0b013e318211c3ae. Epub 2011 Feb 16.

5.

APOE ε4 is associated with longer telomeres, and longer telomeres among ε4 carriers predicts worse episodic memory.

Wikgren M, Karlsson T, Nilbrink T, Nordfjäll K, Hultdin J, Sleegers K, Van Broeckhoven C, Nyberg L, Roos G, Nilsson LG, Adolfsson R, Norrback KF.

Neurobiol Aging. 2012 Feb;33(2):335-44. doi: 10.1016/j.neurobiolaging.2010.03.004. Epub 2010 Apr 14.

PMID:
20395015
6.

APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging.

Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM.

Arch Neurol. 2010 Jan;67(1):93-8. doi: 10.1001/archneurol.2009.913.

7.

The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers.

Martínez MF, Martín XE, Alcelay LG, Flores JC, Valiente JM, Juanbeltz BI, Beldarraín MA, López JM, Gonzalez-Fernández MC, Salazar AM, Gandarias RB, Borda SI, Marqués NO, Amillano MB, Zabaleta MC, de Pancorbo MM.

BMC Neurosci. 2009 Sep 30;10:125. doi: 10.1186/1471-2202-10-125.

8.

Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.

Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D.

Arch Neurol. 2007 Sep;64(9):1306-11.

PMID:
17846270
9.

Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ε4 carriers.

Duits FH, Kester MI, Scheffer PG, Blankenstein MA, Scheltens P, Teunissen CE, van der Flier WM.

J Alzheimers Dis. 2013;36(3):563-70. doi: 10.3233/JAD-122227.

PMID:
23629585
10.

Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset.

van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, van der Flier WM.

Psychol Med. 2009 Nov;39(11):1907-11. doi: 10.1017/S0033291709005492. Epub 2009 Apr 1.

PMID:
19335933
11.

Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele.

Langbaum JB, Chen K, Caselli RJ, Lee W, Reschke C, Bandy D, Alexander GE, Burns CM, Kaszniak AW, Reeder SA, Corneveaux JJ, Allen AN, Pruzin J, Huentelman MJ, Fleisher AS, Reiman EM.

Arch Neurol. 2010 Apr;67(4):462-8. doi: 10.1001/archneurol.2010.30.

12.

APOE-epsilon4 is associated with memory decline in cognitively impaired elderly.

Dik MG, Jonker C, Bouter LM, Geerlings MI, van Kamp GJ, Deeg DJ.

Neurology. 2000 Apr 11;54(7):1492-7.

PMID:
10751265
13.

Impact of APOE epsilon4 on the cognitive performance of a sample of non-demented Puerto Rican nonagenarians.

Carrión-Baralt JR, Meléndez-Cabrero J, Rodríguez-Ubiñas H, Schmeidler J, Beeri MS, Angelo G, Sano M, Silverman JM.

J Alzheimers Dis. 2009;18(3):533-40. doi: 10.3233/JAD-2009-1160.

PMID:
19584451
14.

Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status.

Malek-Ahmadi M, Beach T, Obradov A, Sue L, Belden C, Davis K, Walker DG, Lue L, Adem A, Sabbagh MN.

Curr Alzheimer Res. 2013 Jul;10(6):654-9.

15.

Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.

Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttilä T, Farlow MR, Sfikas N, Ballard C, Greig NH.

Pharmacogenet Genomics. 2008 Apr;18(4):289-98. doi: 10.1097/FPC.0b013e3282f63f29.

PMID:
18334913
16.

Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study.

Myers RH, Schaefer EJ, Wilson PW, D'Agostino R, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL, McNulty KA, Beiser A, Wolf PA.

Neurology. 1996 Mar;46(3):673-7.

PMID:
8618665
17.

APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba.

Hendrie HC, Murrell J, Baiyewu O, Lane KA, Purnell C, Ogunniyi A, Unverzagt FW, Hall K, Callahan CM, Saykin AJ, Gureje O, Hake A, Foroud T, Gao S.

Int Psychogeriatr. 2014 Jun;26(6):977-85. doi: 10.1017/S1041610214000167. Epub 2014 Feb 24.

18.

Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study.

Knopman DS, Mosley TH, Catellier DJ, Coker LH; Atherosclerosis Risk in Communities Study Brain MRI Study.

Alzheimers Dement. 2009 May;5(3):207-14. doi: 10.1016/j.jalz.2009.01.027. Epub 2009 Apr 11.

PMID:
19362884
19.

Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.

Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C.

Dement Geriatr Cogn Disord. 2006;22(1):73-82. Epub 2006 May 12.

20.

Association between ApoE epsilon4 and cognitive impairment after stroke.

Wagle J, Farner L, Flekkøy K, Wyller TB, Sandvik L, Eiklid KL, Fure B, Stensrød B, Engedal K.

Dement Geriatr Cogn Disord. 2009;27(6):525-33. doi: 10.1159/000223230. Epub 2009 Jun 4.

PMID:
19494491

Supplemental Content

Support Center